As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in ...

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...